Amazon stock gets a new Wegovy catalyst — what could move AMZN next week

Amazon.com’s online pharmacy has started selling Novo Nordisk’s newly approved Wegovy weight-loss pill, expanding the retailer’s health services just before the next U.S. trading session.

11 January 2026

Novo Nordisk gets a fresh $73.50 target as Amazon starts selling the Wegovy pill

CICC initiated coverage on Novo Nordisk’s U.S.-listed American depositary receipt — a U.S.-traded certificate that represents shares in a foreign company — with an outperform rating and a $73.50 price target, a Finwire report carried by MarketScreener showed on Friday. Novo’s Copenhagen-listed stock was up about 3%.

9 January 2026

NYSE:NVO·Stock Market

Amazon Pharmacy adds Wegovy pill at $149 cash price, putting Novo Nordisk’s NVO stock back in play

Amazon Pharmacy said on Friday it now offers Novo Nordisk’s Wegovy weight-loss pill through insurance plans and a cash-pay option, with uninsured customers paying from $149 a month and some commercially insured customers paying $25 for a one-month supply. Amazon said it will add the pill to its pharmacy kiosks in the coming weeks and is working with telehealth firms including WeightWatchers, Wheel and 9amHealth; Novo has said the pill will also be available through CVS, Costco and other telehealth services such as Ro, LifeMD and GoodRx. The U.S. FDA approved the once-daily semaglutide pill in December; semaglutide is the active ingredient in injectable Wegovy and diabetes drug Ozempic, and Reuters said the pill’s success is tied to cash-paying consumers who cannot get coverage.

9 January 2026

Amazon·NASDAQ:AMZN·NYSE:NVO·Pharmaceuticals

Amazon stock dips as Amazon Pharmacy adds Novo Nordisk’s Wegovy pill, with $25 insured pricing

Amazon Pharmacy said it now offers Novo Nordisk’s Wegovy pill through insurance plans and a cash-pay option, widening its push into prescription drugs as demand for weight-loss treatments spreads beyond injections. Eligible customers with commercial insurance may pay as little as $25 for a one-month supply, while customers without insurance can buy the pill starting at $149 per month; U.S. regulators approved the 25-milligram semaglutide pill in December, the company said. Amazon.com shares were down 0.7% at $244.58 in early New York trade.

9 January 2026

NASDAQ:AMZN·NYSE:NVO·Pharmaceuticals·Stock Market

Novo Nordisk (NVO) stock rises premarket as Canada platform touts India-sourced Ozempic

Novo Nordisk’s U.S.-listed shares gained 1.4% to $57.34 in premarket trading on Friday after the company rejected claims involving SaveRxCanada.to, a Canadian online pharmacy platform that says it offers India-sourced Ozempic to U.S. patients. SaveRxCanada.to said the pens start at about $280 each, compared with typical U.S. retail prices of $900 to $1,100. A Novo spokesperson said: “We have no customer or partner relationship with this company/platform, and Ozempic from India has not been provided to them.”

9 January 2026

Healthcare News·NYSE:NVO·Pharmaceuticals·Stock Market

Novo Nordisk (NVO) stock jumps as $149 Wegovy pill rollout puts pricing in the spotlight

Novo Nordisk A/S shares listed in New York as ADRs climbed about 4.7% to $57.71 on Tuesday, after touching an intraday high of $58.14.

6 January 2026

Health News·NYSE:NVO·Pharmaceuticals·Stock Market

Novo Nordisk stock jumps premarket as $149 Wegovy pill hits U.S. market

Novo Nordisk’s U.S.-listed shares rose about 4% in premarket trading on Tuesday, extending gains after the Danish drugmaker began selling its once-daily Wegovy weight-loss pill in the United States. The stock was up at $57.29, compared with a prior close of $55.11. Public

6 January 2026

Health News·NYSE:NVO·Pharmaceuticals·Stock Market

Eli Lilly stock slides as Novo’s Wegovy pill hits U.S. market and revives price pressure fears

Eli Lilly and Co shares fell on Monday and were last down 3.6% at $1,041.51 in after-hours trading. The stock weakened as rival Novo Nordisk began rolling out a pill version of its Wegovy weight-loss drug in the United States. The Washington Post

6 January 2026

NYSE:LLY·NYSE:NVO·Pharmaceuticals·Stock Market

Viking Therapeutics stock sinks as Novo’s Wegovy pill debut resets obesity-drug pricing

Shares of Viking Therapeutics slid 9.9% to $31.93 in afternoon trading on Monday as obesity-drug stocks reacted to Novo Nordisk’s U.S. launch of a Wegovy weight-loss pill. Novo’s U.S.-listed shares rose 5.1%, while Eli Lilly fell 3.9% and the SPDR S&P Biotech ETF dropped 2.2%.

5 January 2026

Health News·NASDAQ:VKTX·NYSE:LLY·NYSE:NVO·Pharmaceuticals·Stock Market

Structure Therapeutics stock slides nearly 8% as Novo’s Wegovy pill debut jolts oral obesity-drug bets

Structure Therapeutics shares fell 7.7% to $62.86 in afternoon trade on Monday, paring an earlier rally and marking another volatile session for the obesity-drug developer. The stock has ranged from $72.02 to $62.50 so far in the regular session.

5 January 2026

NASDAQ:STTX·NASDAQ:VKTX·NYSE:LLY·NYSE:NVO·Pharmaceuticals·Stock Market

Eli Lilly stock slides as Novo’s Wegovy pill hits U.S. shelves and stokes obesity-drug pricing fears

Eli Lilly and Company shares fell about 3.4% on Monday, extending early losses after rival Novo Nordisk began selling a pill version of its Wegovy weight-loss drug in the United States. The stock was down at $1,043.14 after dipping nearly 4% earlier in the session.

5 January 2026

NYSE:LLY·NYSE:NVO·Pharmaceuticals·Stock Market

Eli Lilly stock today: LLY slips as China Mounjaro cuts and U.S. pricing reset draw focus

Eli Lilly shares edged lower on Wednesday as investors weighed new signals that blockbuster diabetes and obesity drugs are heading into 2026 with lower price tags in some markets. The stock was down 0.1% at $1,078.95 by 1:48 p.m. ET, after trading between $1,076.86 and $1,083.25.

31 December 2025

NYSE:LLY·NYSE:NVO·Pharmaceuticals·Stock Market

Hims & Hers stock dips in premarket as GLP-1 drug pricing pressure stays in focus

Shares of Hims & Hers Health Inc fell 0.5% to $32.87 in premarket trading on Wednesday after closing down 3.1% at $33.04 in the prior session. The stock has traded between $23.97 and $72.98 over the past 52 weeks. Google

31 December 2025

NYSE:HIMS·NYSE:LLY·NYSE:NVO·Pharmaceuticals·Stock Market

Eli Lilly stock ticks up after hours as China price cuts put Mounjaro, Wegovy in focus

Eli Lilly shares were up 0.1% in after-hours trading on Tuesday at $1,079.75 after a Reuters report said it and Novo Nordisk are lowering prices of their top-selling obesity drugs in China. Reuters

30 December 2025

NYSE:LLY·NYSE:NVO·Pharmaceuticals·Stock Market

Eli Lilly stock dips after report flags China price cuts for Mounjaro

Eli Lilly and Company shares were down $1.73, or about 0.2%, at $1,077.00 in morning trading on Tuesday.

30 December 2025

NYSE:LLY·NYSE:NVO·Pharmaceuticals·Stock Market

Novo Nordisk halves Wegovy prices in parts of China as copycat competition looms

Novo Nordisk said it is lowering prices of its top-selling obesity drug Wegovy in China, after local outlet Yicai reported that list prices for the two highest doses were cut by 48% in the southwestern provinces of Yunnan and Sichuan. The new monthly list prices were 987 yuan and 1,284 yuan, Yicai said, citing local procurement authorities. Reuters

30 December 2025

NYSE:NVO·Pharmaceuticals

Novo Nordisk Stock (NVO): Wegovy Pill FDA Approval, CagriSema Filing, and the 2026 Outlook Investors Are Watching (Dec. 25, 2025)

December 25, 2025 — Christmas Day is a market holiday in the U.S., but Novo Nordisk A/S is still doing what it’s done for most of the past two years: pulling attention toward anything labeled GLP‑1. NASDAQ Trader

25 December 2025

NYSE:NVO·Pharmaceuticals

Eli Lilly Stock (LLY) News on Dec. 24, 2025: GLP‑1 Pill Rivalry, India Expansion, and the Latest Analyst Forecasts

Eli Lilly and Company stock is in the spotlight on December 24, 2025 as investors digest a new round of GLP‑1 headlines that span regulatory momentum, global market expansion, and shifting coverage expectations—all of which feed directly into the long-term demand outlook for Lilly’s obesity and diabetes franchise.

24 December 2025

NYSE:LLY·NYSE:NVO·Pharmaceuticals·Stock Market

Novo Nordisk Stock (NVO) in Focus on Dec. 24, 2025: Wegovy Pill Shockwave, Policy Tailwinds, and Analyst Forecasts

Dec. 24, 2025 — Novo Nordisk A/S has snapped back into the market’s spotlight this week after U.S. regulators cleared a pill version of its blockbuster obesity drug Wegovy—an approval that investors and analysts see as a pivotal moment in the fast-evolving GLP‑1 weight-loss race. But the story driving Novo Nordisk stock today is bigger than a single FDA decision: it’s also about pricing and coverage policy in the U.S., and a global expansion battle—especially in India—where branded GLP‑1s are colliding with the prospect of cheaper generics in 2026. Novo Nordisk+2Reuters+2

24 December 2025

Financial Forecasts·NYSE:NVO·Pharmaceuticals·Stock Market

Eli Lilly Stock (LLY) After Hours Today (Dec. 23, 2025): What Happened After the Bell—and What to Watch Before the Market Opens Dec. 24

Eli Lilly and Company ended Tuesday, December 23, 2025, modestly lower as investors digested a major competitive jolt in the booming obesity-drug market. LLY closed at $1,071.64, down about 0.45%, and was little changed in early after-hours trading. FinancialContent+1

23 December 2025

NYSE:LLY·NYSE:NVO·Stock Market

Previous 1 2 3 4 5 6 … 8 Next

Novo Nordisk gets a fresh $73.50 target as Amazon starts selling the Wegovy pill

Amazon Pharmacy adds Wegovy pill at $149 cash price, putting Novo Nordisk’s NVO stock back in play

Amazon stock dips as Amazon Pharmacy adds Novo Nordisk’s Wegovy pill, with $25 insured pricing

Novo Nordisk (NVO) stock rises premarket as Canada platform touts India-sourced Ozempic

Novo Nordisk (NVO) stock jumps as $149 Wegovy pill rollout puts pricing in the spotlight

Novo Nordisk stock jumps premarket as $149 Wegovy pill hits U.S. market

Eli Lilly stock slides as Novo’s Wegovy pill hits U.S. market and revives price pressure fears

Viking Therapeutics stock sinks as Novo’s Wegovy pill debut resets obesity-drug pricing

Structure Therapeutics stock slides nearly 8% as Novo’s Wegovy pill debut jolts oral obesity-drug bets

Eli Lilly stock slides as Novo’s Wegovy pill hits U.S. shelves and stokes obesity-drug pricing fears

Eli Lilly stock today: LLY slips as China Mounjaro cuts and U.S. pricing reset draw focus

Hims & Hers stock dips in premarket as GLP-1 drug pricing pressure stays in focus

Eli Lilly stock ticks up after hours as China price cuts put Mounjaro, Wegovy in focus

Eli Lilly stock dips after report flags China price cuts for Mounjaro

Novo Nordisk halves Wegovy prices in parts of China as copycat competition looms

Novo Nordisk Stock (NVO): Wegovy Pill FDA Approval, CagriSema Filing, and the 2026 Outlook Investors Are Watching (Dec. 25, 2025)

Eli Lilly Stock (LLY) News on Dec. 24, 2025: GLP‑1 Pill Rivalry, India Expansion, and the Latest Analyst Forecasts

Novo Nordisk Stock (NVO) in Focus on Dec. 24, 2025: Wegovy Pill Shockwave, Policy Tailwinds, and Analyst Forecasts

Eli Lilly Stock (LLY) After Hours Today (Dec. 23, 2025): What Happened After the Bell—and What to Watch Before the Market Opens Dec. 24

TechStock² Updates

Marvell shares fall 10.3% as Google AI-related revenue projected for fiscal 2029

SpaceX Shares Advance 0.5% as $18.4 Billion Capital Spending Outpaces Revenue

American Airlines Shares Edge Down 0.6% Despite Record Revenue, Yielding 0.4% Net Margin

IREN Shares Slide 12.5% as $30 Billion Capex Faces $4 Billion AI Revenue Pace

Disney Stock Rises 1.2% as Pokémon Deal Targets a $4.7 Billion Streaming Base

CME Group Shares Gain 1.7% as Record Trading Volume Lifts Margin to 69.5%

Lululemon Shares Rise 5.1% Despite Earnings Highlighting 410-Basis-Point Margin Decline

Chevron Shares Gain 1.1%, Market Cap Grows by $4.1 Billion as Venezuela Deal Approaches

SoFi Shares Slide 5.8% Despite 43% Revenue Gain as Sales Multiple Hits 4.9x

Plug Power Shares Drop 3.5% After Quarterly Cash Outflow Reduces $162 Million Reserve

Investment Disclaimer